


Our leadership

Driving strategic action and providing oversight

At Sun Pharma, our Directors are at the forefront of driving our commitment to business ethics and sustainable business practices

The Directors stay abreast of emerging concepts and recent developments through cross-functional discussions. The Board collectively spearheads compliance and drives action on our strategic objectives. The Directors formulate and periodically update strategies and policies, taking into account economic, environmental and social considerations. The Board undertakes self-assessments on an annual basis to track management effectiveness and identify areas of improvement to strengthen oversight. In May 2021, Dr. Pawan Goenka and Ms. Rama Bijapurkar were appointed as Independent Directors, further strengthening the Board of our Company. Ms. Rekha Sethi shall be retiring from the Board of Directors of the Company at the ensuing 29th Annual General Meeting on August 31, 2021, on completion of second term of her appointment as an Independent Director.



The Board of Directors



Israel Makov
Chairman, Non-executive and Non-independent Director



Dilip Shanghvi
Managing Director



Sailesh Desai
Whole-time Director



Kalyanasundaram Subramanian
Whole-time Director



Vivek Chaand Sehgal
Non-executive and Independent Director



Dr. Pawan Goenka
Additional Independent Director



Rama Bijapurkar
Additional Independent Director



Sudhir Valia
Non-executive and Non-independent Director



Rekha Sethi
Non-executive and Independent Director



Gautam Doshi
Non-executive and Independent Director



Sustainability governance

We have a well-defined Delegation of Authority (DoA) that embeds accountability, transparency and agility across our business activities. We have established a matrix that details the roles and responsibilities for key personnel to drive environmental, social and economic impact. This approach allows for a consultative and participatory approach to decision-making. The DoA matrix also supports periodic Board oversight across focus areas, such as financial performance, procurement, employee well-being, and community development, among others.

GRI 102-19